A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on tariffs on the industry. Trump's Department of Commerce is looking into ...

Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity pill.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that ... Mochi CEO Myra Ahmad told CNBC that she wasn’t worried about legal action because with compounding ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly (LLY) is among the list of large-cap ... be enough to weaken the threat of tariffs on the sector. "Declare victory and move on [would] be my advice," he said. Anjalee Khemlani is the ...